gatifloxacin has been researched along with atorvastatin in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (75.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Belder, R; Braunwald, E; Breen, J; Cannon, CP; McCabe, CH | 1 |
| Braunwald, E; Cannon, CP; McCabe, CH; Morrow, D; Pfeffer, MA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ridker, PM; Rifai, N; Rose, LM | 1 |
| Clearfield, M | 1 |
| Braunwald, E; Cairns, R; Cannon, CP; Mega, JL; Morrow, DA; Murphy, S; Ridker, PM | 1 |
| Braunwald, E; Cannon, CP; Morrow, DA; Ray, KK; Rifai, N; Sabatine, MS; Shui, A | 1 |
4 trial(s) available for gatifloxacin and atorvastatin
| Article | Year |
|---|---|
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Pravastatin; Proportional Hazards Models; Pyrroles; Risk Factors; Secondary Prevention | 2005 |
Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial.
Topics: Administration, Oral; Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cholesterol, LDL; Cohort Studies; Coronary Restenosis; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Follow-Up Studies; Gatifloxacin; Heptanoic Acids; Humans; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Secondary Prevention; Statistics as Topic; Survival Rate; Treatment Outcome | 2005 |
Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy.
Topics: Aged; Angina, Unstable; Atorvastatin; C-Reactive Protein; Cholesterol; Epidemiologic Methods; Female; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Pravastatin; Pyrroles; Stroke | 2006 |
Long-term prognostic value of neopterin: a novel marker of monocyte activation in patients with acute coronary syndrome.
Topics: Acute Disease; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Biomarkers; Coronary Artery Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Monocytes; Neopterin; Pravastatin; Prognosis; Pyrroles; Risk Factors; Secondary Prevention; Survival Analysis | 2007 |
4 other study(ies) available for gatifloxacin and atorvastatin
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial.
Topics: Angina, Unstable; Anti-Infective Agents; Anticholesteremic Agents; Atorvastatin; Chlamydophila Infections; Chlamydophila pneumoniae; Cholesterol, LDL; Double-Blind Method; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Multicenter Studies as Topic; Myocardial Infarction; Pneumonia, Bacterial; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Research Design | 2002 |
C-reactive protein levels and outcomes after statin therapy.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Coronary Disease; Fluoroquinolones; Gatifloxacin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Multicenter Studies as Topic; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Recurrence; Risk Factors | 2006 |